Shandong Buchang Pharmaceuticals Co Ltd - Asset Resilience Ratio
Shandong Buchang Pharmaceuticals Co Ltd (603858) has an Asset Resilience Ratio of 3.47% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Shandong Buchang Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Check 603858 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Shandong Buchang Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603858 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥679.28 Million | 3.47% |
| Total Liquid Assets | CN¥679.28 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Shandong Buchang Pharmaceuticals Co Ltd maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Buchang Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Buchang Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 1.95% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Shandong Buchang Pharmaceuticals Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Shandong Buchang Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.09% | CN¥403.75 Million ≈ $59.08 Million |
CN¥19.33 Billion ≈ $2.83 Billion |
+0.39pp |
| 2023-12-31 | 1.69% | CN¥354.09 Million ≈ $51.81 Million |
CN¥20.89 Billion ≈ $3.06 Billion |
-1.61pp |
| 2022-12-31 | 3.31% | CN¥726.45 Million ≈ $106.30 Million |
CN¥21.95 Billion ≈ $3.21 Billion |
+1.23pp |
| 2021-12-31 | 2.08% | CN¥498.17 Million ≈ $72.90 Million |
CN¥23.99 Billion ≈ $3.51 Billion |
+0.39pp |
| 2020-12-31 | 1.69% | CN¥386.45 Million ≈ $56.55 Million |
CN¥22.89 Billion ≈ $3.35 Billion |
-0.14pp |
| 2019-12-31 | 1.82% | CN¥386.45 Million ≈ $56.55 Million |
CN¥21.19 Billion ≈ $3.10 Billion |
+1.76pp |
| 2017-12-31 | 0.07% | CN¥13.00 Million ≈ $1.90 Million |
CN¥19.20 Billion ≈ $2.81 Billion |
-0.47pp |
| 2016-12-31 | 0.54% | CN¥100.00 Million ≈ $14.63 Million |
CN¥18.67 Billion ≈ $2.73 Billion |
-- |
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.